A Phase II Trial of Exploring the Predictive Factors of TX and XELOX Regimen in the First Line Treatment of MGC

Inclusion Criteria: * Chemo-naive patients with metastatic, unresectable, histologically confirmed gastric or Gastroesophageal adenocarcinoma; Patients who received adjuvant chemotherapy, the duration from the last therapy to relapse at least longer than 6 months * Patient must have at least one measurable lesions (RECIST 1.1) * 18 Years to 75 years * Written informed consent obtained * Eastern Cooperative Oncology Group (ECOG) performance status 0-1 * Patients must have adequate organ and marrow function as defined below: * neutrophilicgranulocyte greater than/equal to 1,500/mm3; * platelets greater than/equal to 90,000/ mm3; * hemoglobin greater than/equal to 9 gm/dL (may be transfused to maintain or exceed this level); * total bilirubin less than/equal to 1.5 within institutional upper limit of normal (IULN); * Aspartate Transaminase (AST,SGOT)/Alanine transaminase (ALT,SGPT) less than/equal to 2.5 times IULN * serum creatinine less than/equal to 1.5 x IULN. Exclusion Criteria: * Active clinically serious infections (\> grade 2 NCI-CTC version 3.0, National Cancer Institute-Common Terminology Criteria for Adverse Events) * Symptomatic metastatic brain or meningeal tumors * History of organ allograft * Patients undergoing renal dialysis * chronic inflammatory bowel disease; ileus; genetic fructose intolerance * Patients who received adjuvant chemotherapy and the duration from the last therapy less than 6 months * Receive previously radiotherapy in measurable regions * Pregnancy or lactating status * Concurrent malignancy other than nonmelanoma skin cancer, or in situ cervix carcinoma * Clinically relevant coronary artery disease or history of a myocardial infarction within the last 12 months * Acute or subacute intestinal occlusion or history of the inflammatory bowel disease * Any factors that influence the usage of oral administration